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Objectives: Cholesterol-rich nanoemulsions (LDE) bind to low-density lipoprotein (LDL) 
receptors and after injection into the bloodstream concentrate in aortas of atherosclerotic rabbits. 
Association of paclitaxel with LDE markedly reduces the lesions. In previous studies, treat-
ment of refractory cancer patients with etoposide associated with LDE had been shown devoid 
of toxicity. In this study, the ability of etoposide to reduce lesions and inflammatory factors in 
atherosclerotic rabbits was investigated.
Methods: Eighteen New Zealand rabbits were fed a 1% cholesterol diet for 60 days. Starting 
from day 30, nine animals were treated with four weekly intravenous injections of etoposide 
oleate (6 mg/kg) associated with LDE, and nine control animals were treated with saline 
solution injections.
Results: LDE-etoposide reduced the lesion areas of cholesterol-fed animals by 85% and 
intima width by 50% and impaired macrophage and smooth muscle cell invasion of the intima. 
Treatment also markedly reduced the protein expression of lipoprotein receptors (LDL receptor, 
LDL-related protein-1, cluster of differentiation 36, and scavenger receptor class B member 1), 
inflammatory cytokines (interleukin-1β and tumor necrosis factor-α), matrix metallopeptidase-9, 
and cell proliferation markers (topoisomerase IIα and tubulin).
Conclusion: The ability of LDE-etoposide to strongly reduce the lesion area and the 
inflammatory process warrants the great therapeutic potential of this novel preparation to target 
the inflammatory-proliferative basic mechanisms of the disease.
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Atherosclerosis is currently considered a chronic inflammatory-proliferative 
disease.1,2 The quest for anti-inflammatory antiproliferative agents that effectively 
achieve reduction of atherogenesis has been growing.3 Among other strategies, 
chemotherapeutic agents that are used in cancer treatment have also been tested in 
experimental models of atherosclerosis. Compounds such as paclitaxel and etoposide 
were shown to promote reduction of lesions in rabbits made atherosclerotic by high 
cholesterol feeding.4 However, those agents also convey high toxicity levels that 
discourage their potential use in cardiovascular therapeutics.
In previous studies, we have shown that a cholesterol-rich nanoemulsion, termed 
LDE, that roughly resembles the lipidic structure of low-density lipoprotein (LDL) 
is taken up by the LDL receptors after injection into the bloodstream.5 Although 
made without protein, in contact with plasma, LDE acquires several exchangeable 
apolipoproteins, such as apo E that is recognized by LDL receptors or by LDL-related 
protein (LRP)-1 receptors;6 LDE is then internalized into cells by the receptor-mediated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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endocytic mechanism. As most cancer cell lines show LDL 
receptor upregulation, LDE can be used as a vehicle to direct 
antineoplastic drugs to those cells, as demonstrated in breast 
and ovary carcinoma tissues7,8 as well as in hematologic 
cancers such as acute myelocytic leukemia and multiple 
myeloma.9,10 Association to LDE of drugs such as carmustine, 
etoposide, and paclitaxel pronouncedly reduces the toxicity 
of those agents while preserving or even increasing the 
antineoplastic activity, as shown in tumor-implanted rats 
and mice.11–13
In a subsequent study, we showed that LDE can also 
concentrate in the lesioned aortas of cholesterol-fed rabbits 
after injection into the blood circulation. Treatment of the 
atherosclerotic rabbits with the association of paclitaxel to 
LDE resulted in marked reduction of the atherosclerotic 
lesions.14 Concentration in the lesioned aorta segments occurs 
because LDL-receptor overexpression is not restricted to 
neoplastic tissues: it possibly takes place whenever a greater 
cell input of cholesterol and other lipids for membrane 
building is required to assist the increased mitosis rates in 
proliferative processes. Zhu et al observed overexpression 
of LDL receptors in smooth muscle cells of the hyperplastic 
intima.15
Reduction of toxicity of chemotherapeutic agents by 
associating them to LDE was confirmed at clinical level. In 
trials enrolling patients with advanced cancers treated with 
LDE-carmustine,10 LDE-paclitaxel,16 and LDE-etoposide,17 
the toxicity of high-dose treatments was minimal or absent. 
Together with the demonstration that LDE can concentrate 
in atherosclerotic lesions, those findings paved the way for 
experiments aiming to test the powerful antiproliferative 
weaponry in atherosclerosis therapeutics.
In this study, the effects of the association to LDE of 
etoposide on atherosclerotic lesions and on the   protein expression 
of inflammatory markers were tested in cholesterol-fed rabbits. 
Etoposide is a semisynthetic derivative of podophyllotoxin that 
causes double strand deoxyribonucleic acid (DNA) brakes by 
an association with topoisomerase IIα and DNA, leading to cell 
cycle block and cell death.18 Similarly to paclitaxel,   etoposide is 
poorly incorporated into nanoemulsions. To optimize the yield 
of the incorporation to LDE and the stability of the formed 
association, lipophilicity of etoposide was increased by 
derivatizing the agent with an oleyl group.
Methods
Animals and experimental protocols
Eighteen male New Zealand White rabbits weighing 
3.4 ± 0.3 kg (mean ± standard deviation [SD]) were housed 
in individual cages in a temperature-controlled room 
(20°C–22°C) and on a 12-hour light–dark cycle during the 
experimental period. The animals were fed a diet consisting of 
regular feed with added 1% cholesterol (w/w) for 60 days.
On day 30, animals were separated into two groups. Nine 
animals were treated with four weekly intravenous injections 
of LDE-etoposide (6 mg/kg and 30 mg of total lipids), 
and nine animals received four weekly intravenous saline 
solution in equivalent volume. One week after the last dose 
of the treatment, the euthanasia was performed by a lethal 
intravenous dose of 80 mg/kg of sodium pentobarbital.
The amount of feed was restricted to 150 g. The food 
intake was assessed daily, and bodyweight was assessed 
weekly.
This protocol conforms to the Guide for the Care and Use 
of Laboratory Animals (US National Institutes of Health) 
and was approved by the Ethics Committee of University 
of São Paulo.
Plasma lipids and blood cell counting
After overnight fasting, blood samples were taken for 
determination of total and high-density lipoprotein (HDL) 
cholesterol and triglycerides by commercial kits (Labtest, 
São Paulo) and for blood cell count.
Preparation of LDe and association  
of etoposide to LDe
LDE was prepared according to the method described by 
Maranhão et al.19 A lipid mixture of 40 mg cholesteryl 
oleate, 20 mg egg phosphatidylcholine, 1 mg triolein, and 
0.5 mg cholesterol was emulsified in aqueous medium by 
prolonged ultrasonic irradiation for 3 hours. A two-step 
ultracentrifugation (195,000 × g for 30 minutes followed by 
195,000 × g for 120 minutes in a TH 641 [Thermo Scientific, 
Waltham, MA] rotor at 4°C) of the crude emulsion with 
density adjustment by addition of solid KBr was done to 
obtain the LDE nanoemulsion. LDE was dialyzed overnight 
against 2 L of 10 mM tris-HCl buffer pH 8.0 for KBr extrac-
tion, and sterilized by passing through a 0.22 µm filter.
Etoposide (6 mg) was associated to nanoemulsion (1 mL, 
30 mg of total lipids) by solubilization of etoposide in 
ethanol (10% v:v).20 Etoposide was added to the emulsion. 
The solution was sonicated for 1 hour at 70°C using a 
Sonifier® 450 (Branson Ultrasonics, Danbury, CT), equipped 
with a 1 cm flat titanium probe. The resultant mixture was 
centrifuged at 3,500 rpm for 15 minutes to separate free 
etoposide. Etoposide loaded nanoemulsion was then passed 
through 0.22 µm pore filter and kept at 4°C. The amount of International Journal of Nanomedicine 2011:6
Table  1  serum  lipids  of  rabbits  treated  with  LDe-etoposide   
(6 mg/kg body weight/week) or saline solution (control group), 
for 8 weeks
Control (n = 9) LDE-etoposide (n = 9)
Baseline 8th week Baseline 8th week
Total cholesterol 42 ± 29 1369 ± 279a 36 ± 25 2250 ± 321a,b
hDL-cholesterol 13 ± 8     18 ± 8 12 ± 4     19 ± 6
Triglycerides 53 ± 33   354 ± 231c 35 ± 48   694 ± 234a
Notes: Data are expressed as mean ± sD. aP , 0.001 versus baseline; bP , 0.001 
versus 8th week control; cP , 0.05 versus baseline.
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drug associated to the nanoemulsion was always measured 
by high-performance liquid chromatography before injection. 
The yield of association was 85% and the particle diameter, 
measured by laser light scattering, was about 60 nm.
Analysis of lesion areas
Aorta was excised from the aortic arch to the abdominal artery, 
opened longitudinally, washed with saline, and placed in 10% 
buffered formalin. After fixation, the aorta was stained in 
Scarlet R, and pictures were taken to   measure the lesions. The 
aortic arch was sectioned in 5 mm segments and embedded 
in paraffin. Sections taken for each segment were stained in 
hematoxylin-eosin for total area measurement. Additional 
sections were stained with anti-LRP-1 (Calbiochem, 
Darmstadt, Germany), anti-LDL receptor (Lifespan, 
Seattle, WA), anti-rabbit macrophage (RAM-11 clone) 
(Dako, Carpinteria, CA), anti-matrix metallopeptidase 
9 (MMP9) (AbCam, Cambridge, MA), anti-tumor necrosis 
factor (TNF)-α (R&D Systems, Minneapolis, MN), anti-
interleukin (IL)-1β (R&D Systems), anti-tubulin (AbCam), 
anti-scavenger receptor class B member 1 (SR-B1) 
(Millipore, Billerica, MA), anti-proliferating cell nuclear 
antigen (PCNA) (AbCam), anti-cluster of differentiation 
36 (CD36) (Genetex, Irvine, CA), anti-α actin (Dako), and 
anti-topoisomerase IIα (AbCam). All measurements were 
performed using Leica QWin Image Analysis Software 
(Leica Microsystems, Wetzlar, Germany).
statistical analysis
Comparison between groups of lipid and hematological pro-
files and bodyweight was assessed by one-way analysis of 
variance with Tukey post test. All other analysis was assessed 
using the Student’s t-test. In all analysis, difference of two-
tailed P below 0.05 was considered statistically significant. 
Values were expressed as mean ± SD.
Results
Plasma lipids
As shown in Table 1, total cholesterol concentration in the 
cholesterol fed rabbits increased 20-fold in the group treated 
with LDE-etoposide and tenfold in the control group from 
baseline to the end of the 8th week of the cholesterol feed-
ing period. In contrast, HDL cholesterol was unchanged in 
both groups. After the 8-week period, triglyceride values 
were increased by the diet about tenfold in both groups. It 
is worthwhile to point out that there were no differences in 
the plasma lipids when controls and LDE-etoposide treated 
rabbits were compared at baseline and at 8 weeks.
Toxicity evaluation
Compared with baseline, after the 8-week experimental 
period the food intake increased by 15% in both LDE-
etoposide and control groups (Figure 1), but the bodyweight 
was unchanged.
The red blood cell count of the animals treated with LDE-
etoposide fell by 50% and was not significantly altered in 
the control group. On the other hand, leukocyte count did 
not diminish in both LDE-etoposide and control groups as 
shown in Table 2.
evaluation of atherosclerotic lesions
Figure 2 shows the aorta of a rabbit treated with LDE-
etoposide and that of a control rabbit. By comparing against 
the controls, LDE-etoposide treatment reduced the lesions 
by 85% as analyzed by macroscopic morphometry, as shown 
in Table 3.
Table 4 presents the results of the microscopic analysis 
of segments of the aortic arch of rabbits treated with LDE-
etoposide and those of controls. The computer-assisted micro-
scopic morphometric analysis showed that the LDE-etoposide 
reduced the intima layer area by 75%. LDE-etoposide 
treatment did not affect the area of the media layer.
Figures 3 and 4 show the photomicrographs of stained 
intimal areas of aortic arch tissues stained for different 
antibodies. In Table 5, there are the percentages of stained 
areas of each one of the antibody labels calculated by a 
computer assisted morphometry technique.
LDE-etoposide treatment reduced macrophage presence 
by 50% (67.73% ± 13.03% of stained area in controls 
and 26.96% ± 28.46% in LDE-etoposide treated rabbits, 
P , 0.01). The percentage of stained area by vascular 
smooth muscle cells (VSMCs) was reduced by 60% 
(27.52% ± 10.63% in the control group and 7.89% ± 9.06% 
in the LDE-etoposide group, P , 0.05).
LDE-etoposide also reduced the expression of the LDL 
receptors by 60% (35.13% ± 20.13% in the control group and International Journal of Nanomedicine 2011:6
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Figure 1 Food intake (A) and bodyweight (B) of rabbits treated with LDe-etoposide or saline solution (control group) over an 8-week period. 
Abbreviation: LDe, cholesterol-rich nanoemulsion.
Table 2 Hematological profile of rabbits treated with LDE-etoposide (6 mg/kg body weight/week) or saline solution (control group), 
for 8 weeks
Control (n = 9) LDE-etoposide (n = 9)
Baseline 8th week Baseline 8th week
red blood cells (109/mL)   5.7 ± 1.0   4.4 ± 1.6   6.0 ± 1.0   2.9 ± 0.8a,b
Leuckocytes (106/mL)   6.6 ± 1.0   7.6 ± 3.1   7.6 ± 3.5   6.9 ± 2.9
  Lymphocytes (%) 72.8 ± 4.7 62.7 ± 11.6 68.2 ± 7.9 73.7 ± 9.9
  Monocytes (%)   5.6 ± 5.0 10.8 ± 5.4   7.0 ± 3.9   5.9 ± 3.7
  Neutrophils (%) 18.9 ± 9.9 26.6 ± 10.2 25.9 ± 7.4 20.4 ± 9.3
Notes: Data are expressed as mean ± sD. aP , 0.001 versus baseline; bP , 0.001 versus 8th week control.
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11.28% ± 16.80% in the LDE-etoposide group, P , 0.05) 
and of the LRP-1 receptor by 90% (41.94% ± 21.35% in 
the control group and 5.11% ± 9.92% in the LDE-etoposide 
group, P , 0.001). In respect to the expression of 
scavenger receptors, LDE-etoposide reduced CD36 by 80% 
(40.13% ± 15.26% in the control group and 8.60% ± 13.54% 
in the LDE-etoposide group, P , 0.001) and SR-B1 by 80% 
(19.86% ± 8.26% in the controls and 4.87% ± 8.65% in the 
LDE-etoposide treated rabbits, P , 0.01).
Regarding the expression of inflammatory cytokines, 
IL-1β protein was reduced by 50% (55.41% ± 17.82% in the 
control group and 24.82% ± 22.69% in the LDE-etoposide 
group, P , 0.01) and TNF-α by 75% (20.04% ± 15.77% 
in the control group and 5.57% ± 6.42% in the LDE-
etoposide group, P , 0.001). MMP9 protein expression 
was reduced by 50% (14.98% ± 8.59% in the control group 
and 6.44% ± 8.41% in the LDE-etoposide group, P , 0.05). 
As to the expression of proteins related with cell prolif-
eration, tubulin was reduced by 80% (47.40% ± 15.38% 
in the control group and 16.01% ± 19.82% in the LDE-
etoposide group, P , 0.01) and topoisomerase IIα by 60% 
(42.46% ± 15.77% in the control group and 8.51% ± 10.35% 
of stained area in the LDE-etoposide group, P , 0.001); 
PCNA was equal in LDE-etoposide treated and control 
animals.
Discussion
In this study, it was shown that in aortas of cholesterol-fed 
rabbits, LDE-etoposide at the 6 mg/kg bw weekly dose for 
4 weeks was able to reduce by 85% the total lesion area as 
measured by macroscopic morphometry. De la Llera-Moya 
et al21 reported that the treatment of cholesterol-fed rabbits 
with a conventional commercial etoposide preparation at a 
much larger dose (40 mg/kg bw/week dose administered for 
8 weeks) than that used in this present study resulted in a 50% 
lesion area reduction, which is a very marked difference in 
effectiveness of the treatments.
Differently from the protocol used in this present study, 
the etoposide treatment was introduced 1 week before the 
beginning of the cholesterol feeding, which leads to a pre-
ventive rather than curative treatment approach. Anyhow, 
the largely known toxicity spectrum of etoposide, which 
encompasses myelosuppression, gastrointestinal symptoms, 
hypotension, and allergic reactions prohibits the introduction International Journal of Nanomedicine 2011:6
Table 4 Microscopic morphometry (intima and media layers) 
of aorta of rabbits treated with LDe-etoposide (6 mg/kg body 
weight/week) or saline solution (control group), for 8 weeks
Control  
(n = 9)
LDE-etoposide   
(n = 9)
Total area (µm2) (×103) 0.40 ± 0.05 0.30 ± 0.02a
Media layer area (µm2) (×103) 0.30 ± 0.04 0.28 ± 0.01
Intima layer area (µm2) (×103) 0.10 ± 0.01 0.03 ± 0,01b
Intima/media area 0.30 ± 0.04 0.10 ± 0.03a
Notes: Data are expressed as mean ± sD. aP , 0.01; bP , 0.001 versus control.
Figure 2 Aortas of rabbits treated with (A) saline solution (control group) or   
(B) LDe-etoposide, for 8 weeks, stained by scarlet red. 
Abbreviation: LDe, cholesterol-rich nanoemulsion.
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of this drug in the vehicle used in the commercial formulation 
in the cardiology field.22
In this study, anemia was the only observed toxicity 
documented in the animals after the LDE-etoposide treatment. 
Other toxicities under scrutiny here, such as weight loss, 
diminished food intake, leukopenia, and clinically observable 
alterations, were absent. In fact, in the classical toxicologi-
cal tests conducted in mice, the toxicity of etoposide was 
pronouncedly reduced by association with LDE. The novel 
formulation showed maximum tolerance dose and 50% lethal 
dose roughly five times that of the commercial etoposide 
formulation.12,20 Moreover, the toxicity of LDE-etoposide was 
also tested in a small safety study in two patients with refrac-
tory lymphoma. In the etoposide, 300 mg/m2 dose/3 weeks, 
administered over 6 cycles.17 This dose scheme corresponds 
to those routinely used in the clinical oncology practice. 
During the treatment, no clinical and laboratorial toxicities, 
including anemia or other myelotoxicities, were observed 
in both patients. Interestingly, anemia not accompanied 
by leucopenia was the only prominent toxicity found in 
atherosclerotic rabbits treated with commercial etoposide 
reported by De la Llera-Moya et al.21 Apparently, this may 
be a species-related toxicity trait that, as we have shown in 
our previous studies, did not appear in our LDE-etoposide 
treated patients.17
In patients with ovarian carcinoma, the plasma decay 
curve of etoposide associated with LDE was markedly 
slower than that of the commercial formulation, as shown 
by Azevedo et al.23 In that study, it was shown that etopo-
side oleate did not dissociate from LDE while in the blood 
stream. LDE-etoposide pharmacokinetic parameters favor the 
novel formulation, since extension of half-life of etoposide 
achieved by the association to LDE may be an interesting 
feature in favoring the pharmacological action in chronic 
diseases.
The antiatherosclerotic effects of LDE-etoposide, at the 
order of 85% lesion area reduction, were apparently greater 
than those of LDE-paclitaxel described in a previous study. 
LDE-paclitaxel achieved a 60% reduction of the lesion area.14 
By performing statistical analysis with the data obtained 
in the two studies, this difference was found significant at 
P = 0.02.
Similarly to the LDE-paclitaxel experiment in a previous 
study by the same authors,14 LDE-etoposide could not only 
inhibit the VSMC proliferation and invasion of the intima 
but also the massive macrophage presence in the intima. 
This results in the reduction of the intima width that was 
statistically equal to that observed in the LDE-paclitaxel 
treatments. In respect to the media, thickening of this arterial 
layer is not involved in atherogenesis, so the finding that 
LDE-etoposide treatment did not change media width was 
indeed expected.
The finding of overall reduction of the protein expression 
of the receptors tested here, namely LDL receptor, LRP-1, 
CD36, and SR-B1, by LDE-etoposide may simply mirror 
the decrease in the cellularity of the intima, rather than 
diminution of receptor number/cell. Apparently, the effect of 
treatment was greater on the expression of LRP-1 than on the 
expression of the other receptors, a finding that could suggest 
a selective effect on the receptor rather than diminution of 
Table 3 Macroscopic morphometry of aorta in rabbits treated 
with  LDe-etoposide  (6  mg/kg  body  weight/week)  or  saline 
solution (control group), for 8 weeks
Control  
(n = 9)
LDE-etoposide   
(n = 9)
Total area of aorta (pixel2 × 106) 0.54 ± 0.44 1.05 ± 0.17
Lesion area (pixel2 × 106) 0.40 ± 0.32 0.06 ± 0.04
Lesion/total area 0.68 ± 0.17 0.06 ± 0.04a
Notes: Data are expressed as mean ± sD. aP , 0.001 versus control.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 4 Immunohistochemistry of artery tissues from rabbits treated with saline solution (control group) or LDe-etoposide. Photomicrographs of diaminobenzidine 
chromogen immunostaining for MMP9, IL-1β, TNF-α, PcNA, topoisomerase IIα, tubulin. Magnifications: 100×. 
Abbreviations: IL, interleukin; LDe, cholesterol-rich nanoemulsion; MMP9, matrix metallopeptidase 9; PcNA, proliferating cell nuclear antigen; TNF, tumor necrosis 
factor.
Macrophages
Control
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Figure 3 Immunohistochemistry of artery tissues from rabbits treated with saline solution (control group) or LDe-etoposide. Photomicrographs of diaminobenzidine 
chromogen immunostaining for macrophages, VSMC, LDL receptor, LRP-1, CD36, and SR-B1. Magnifications: 100×. 
Abbreviations: cD36, cluster of differentiation 36; LDe, cholesterol-rich nanoemulsion; LDL, low-density lipoprotein; LrP, LDL-related protein; sr-B1, scavenger receptor 
class B member 1; VsMc, vascular smooth muscle cells.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cell number. LDL receptors are typically found in VSMCs, 
whereas CD36 is characteristically a macrophage   receptor.24 
The fact that the protein expression of both receptors 
diminished equally reflects the post-treatment diminution of 
both VSMC and macrophages that was also equal.
The evaluation of pro-inflammatory cytokines IL-1β 
and TNF-α showed that LDE-etoposide treatment was 
effective in impairing the protein expression of both. IL-1β 
is primarily a macrophage-secreted cytokine, whereas 
TNF-α is produced by diverse cell lines present in the 
inflammation site.25 Impairment of cytokine production can 
be also related with the diminution of their secreting cells by 
treatment. MMP9 protein expression was also diminished 
by the treatment. It is produced by macrophages during 
inflammation. The secretion of inflammatory cytokines 
impairs the production of collagen and other structural 
proteins by VMSC and increases the expression of MMP9 
and other metalloproteinases.2 Therefore, the treatment 
with the novel etoposide formulation promotes an overall 
inhibition of pro-inflammatory proteins.
The protein expression of two of the three cell proliferation 
markers analyzed here was inhibited by LDE-etoposide 
treatment, namely the structural protein tubulin that is 
overexpressed during mitosis26 and topoisomerase IIα, that 
is overexpressed during DNA synthesis.27 Those results 
convey the strong effect of the treatment that consisted 
in the inhibition of the massive invasion of the intima by 
macrophages and VSMCs. Unexpectedly, the treatment 
did not inhibit PCNA which is a classical marker of DNA 
synthesis.28 It was worthwhile to point out, however, that the 
expression of this protein was low in the control group.
Etoposide stabilizes the complex formed between DNA and 
topoisomerase II, which leads to accumulation of strand breaks 
in DNA. Etoposide treatment prevents cells from entering 
mitosis, thus slowing down the progression of the cell cycle, 
with arrest in G2 phase.29 However, the effects of the drug in 
nonneoplastic proliferating tissues and inflammatory sites are 
largely unexplored. The antiproliferative effect of etoposide 
may account for the decrease in atheroma formation in 
the treated rabbits by proliferation inhibition of smooth muscle 
cells, macrophages, and macrophage-derived foam cells.21
In conclusion, LDE-etoposide was effective in reducing 
the rabbit atherosclerotic lesions by strongly diminishing 
the proliferation in the intima of VSMC and macrophages, 
decreasing the production of pro-inflammatory factors such 
as IL-1β, TNF-α, and MMP9. Lipoprotein receptors and 
proliferation markers were also inhibited by the treatment. 
Because the safety of LDE-etoposide treatment has already 
been shown not only in animal experiments but also in a 
pilot clinical study, with excellent tolerability, this novel 
formulation of etoposide can offer a promising strategy for 
the treatment of atherosclerotic cardiovascular disease.
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IL-1β 55.41 ± 17.82 24.82 ± 22.69b
TNF-α 20.04 ± 15.77   5.57 ± 6.42c
MMP-9 14.98 ± 8.59   6.44 ± 8.41a
PcNA   3.53 ± 3.90   4.51 ± 4.55
Topoisomerase IIα 42.46 ± 15.77   8.51 ± 10.35c
Tubulin 47.40 ± 15.38 16.01 ± 19.82b
LDL receptor 35.13 ± 20.13 11.28 ± 16.80a
LrP-1 41.94 ± 21.35   5.11 ± 9.92c
cD-36 40.13 ± 15.26   8.60 ± 13.54c
sr-B1 19.86 ± 8.26   4.87 ± 8.65b
Notes: Data are expressed as mean ± sD. aP , 0.05 versus control; bP , 0.01 versus 
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